Annexon, Inc.
Close on Oct 19, 2026
- Market cap
- $806.02M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
About Annexon
Pharmaceutical Preparations, SIC 2834
Annexon, Inc. is a clinical-stage biopharmaceutical company that discovers and develops targeted immunotherapies for complement-mediated neuroinflammatory disorders. The company focuses on inhibiting C1q, the initiating molecule of the classical complement cascade, to treat conditions across three primary therapeutic areas: autoimmune disorders, neurodegeneration, and ophthalmology. Its product candidates include tanruprubart for Guillain-Barré syndrome, vonaprument for geographic atrophy, and ANX1502, an oral small molecule being studied for cold agglutinin disease. Annexon also evaluates therapeutic candidates for Huntington’s disease, amyotrophic lateral sclerosis, and lupus nephritis. Its treatments are designed for patients affected by severe neuroinflammatory diseases.
Annexon conducts clinical and regulatory operations internationally, with clinical trial activity spanning the United States, Europe, and Southeast Asia. The company maintains its principal executive offices in Brisbane, California.
Summary of the business section of Annexon's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Annexon, Inc.
- Headquarters
- Brisbane, CA
- Address
- 1400 Sierra Point Parkway, Bldg C, Suite 200 94005
- Phone
- (650) 822-5500
- Website
- annexonbio.com
- Employees
- 96, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Francisco, CA
Stock & identifiers
- Ticker
- ANNX
- Exchange
- Nasdaq
- IPO date
- Jul 24, 2020
- Shares outstanding
- 204M, Aug 10, 2026
- Public float
- $244.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1528115
- CUSIP
- 03589W102
- ISIN
- US03589W1027
- EIN
- 27-5414423
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Douglas Love | PRESIDENT AND CEO, Director | 390,476 |
| Ted Yednock | EVP & CHIEF INNOVATION OFFICER | 184,807 |
| Jamie Dananberg | CHIEF MEDICAL OFFICER | 123,582 |
| Jennifer Lew | EVP & CHIEF FINANCIAL OFFICER | 170,700 |
| Michael Overdorf | EVP & CHIEF BUSINESS OFFICER | 182,625 |
| Dean Richard Artis | EVP & CHIEF SCIENTIFIC OFFICER | 180,093 |
| Mark S. Blumenkranz | Director | – |
| William A. Jones Jr | Director | – |
| Jung Choi | Director | 33,000 |
| William H. Carson | Director | 78,405 |
| William D. Waddill | Director | – |
| Bettina M. Cockroft | Director | – |
| Muneer A. Satter | Director | 10,342,134 |
| Thomas G. Wiggans | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Douglas Love | $3.58M | $5.08M | $1.36M | $20 | – |
| FY2024 Douglas Love | $3.67M | $4.37M | $1.56M | $21 | – |
| FY2023 Douglas Love | $2.45M | $1.20M | $1.48M | $18 | – |
| FY2022 Douglas Love | $3.58M | $272.10K | $1.42M | $21 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 96 full-time employees, 77 of whom were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 24, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 21, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |